Show simple item record

dc.contributor.authorGu, Maggie
dc.contributor.authorTorres, Jonathan L
dc.contributor.authorLi, Yijia
dc.contributor.authorRy, Alex Van
dc.contributor.authorGreenhouse, Jack
dc.contributor.authorWallace, Shannon
dc.contributor.authorChiang, Chi-I
dc.contributor.authorPessaint, Laurent
dc.contributor.authorJackson, Abigail M
dc.contributor.authorPorto, Maciel
dc.contributor.authorKar, Swagata
dc.contributor.authorLi, Yuxing
dc.contributor.authorWard, Andrew B
dc.contributor.authorWang, Yimeng
dc.date.accessioned2021-10-28T18:23:08Z
dc.date.available2021-10-28T18:23:08Z
dc.date.issued2021-10-15
dc.identifier.urihttp://hdl.handle.net/10713/17007
dc.description.abstractA COVID-19 vaccine with capability to induce early protection is needed to efficiently eliminate viral spread. Here, we demonstrate the development of a nanoparticle vaccine candidate, REVC-128, in which multiple trimeric spike ectodomain with glycine (G) at position 614 were multimerized onto a nanoparticle. In-vitro characterization of this vaccine confirms its structural and antigenic integrity. In-vivo immunogenicity evaluation in mice indicates that a single dose of this vaccine induces potent serum neutralizing antibody titer at two weeks post immunization, which is significantly higher than titer induced by trimeric spike protein without nanoparticle presentation. The comparison of serum binding to spike subunits between animals immunized by spike with and without nanoparticle presentation indicates that nanoparticle prefers the display of spike RBD (Receptor-Binding Domain) over S2 subunit, likely resulting in a more neutralizing but less cross-reactive antibody response. Moreover, a Syrian golden hamster in-vivo model for SARS-CoV-2 virus challenge was implemented at two weeks post a single dose of REVC-128 immunization. The results showed that vaccination protects hamsters against SARS-CoV-2 virus challenge with evidence of steady body weight, suppressed viral loads and alleviation of tissue damage for protected animals, compared with ∼10% weight loss, high viral loads and tissue damage in unprotected animals. Furthermore, the data showed that vaccine REVC-128 is thermostable at up to 37°C for at least 4 weeks. These findings, along with history of safety for protein vaccines, suggest that the REVC-128 is a safe, stable and efficacious single-shot vaccine candidate to induce the earliest protection against SARS-CoV-2 infection.en_US
dc.description.urihttps://doi.org/10.1080/22221751.2021.1994354en_US
dc.language.isoenen_US
dc.publisherTaylor and Francis Inc.en_US
dc.relation.ispartofEmerging Microbes & Infectionsen_US
dc.subjectAntibody-dependent Enhancement (ADE)en_US
dc.subjectCOVID-19 vaccineen_US
dc.subjectNanoparticle vaccineen_US
dc.subjectOne-dose regimenen_US
dc.subjectSARS-CoV-2en_US
dc.subjectVaccine safetyen_US
dc.subjectVaccine stabilityen_US
dc.subjectVariantsen_US
dc.titleOne dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunizationen_US
dc.typeArticleen_US
dc.identifier.doi10.1080/22221751.2021.1994354
dc.identifier.pmid34651563
dc.source.beginpage1
dc.source.endpage35
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record